Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Merck KGaA. (4/23/18). "Press Release: Merck Receives Patent for CRISPR Technology in China". Darmstadt.

Region Region China
Organisation Organisation Merck Life Science Business
  Group Merck (DE) (Group)
Products Product CRISPR gene editing technology
  Product 2 IP services
Persons Person Batra, Udit (Merck (DE) 201507– Head Life Science Business before CEO Merck Millipore + Novartis + JnJ + McKinsey)
  Person 2 Schrimpf, Gangolf (Merck (DE) 201708)
     


> Patent in China covers integration of an external DNA sequence into the chromosome of eukaryotic cells

> Company to license CRISPR-related patents to interested parties, supports genome-editing research under ethical and legal standards

> Foundational CRISPR patents now granted in seven markets, including Canada and Europe


Merck, a leading science and technology company and leader in genome editing, today announced that the Chinese Patent Office has issued a notice granting Merck’s patent application for the company’s CRISPR technology used in a genomic-integration method for eukaryotic cells.

“Including China, we have received seven crucial patents for our foundational CRISPR technology, which defines an exciting new path for medical research and treatments for some of the toughest medical conditions, including cancer, hereditary and rare diseases,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “As a genome-editing leader, we are actively licensing our integration patents for therapeutic use, basic science research and agricultural biotechnology.”

Merck, which has a 13-year history in the genome-editing field, has related patent filings for its insertion CRISPR method in the U.S., Brazil, India and Japan. The company already has had similar key patents granted in Australia, Canada, Europe, Israel, Singapore and South Korea.

This forthcoming patent in China covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR. Scientists can replace a disease-associated mutation with a beneficial or functional sequence — a method important for creating disease models and gene therapy. Additionally, the method can be used to insert transgenes that label endogenous proteins for visual tracking within cells.

CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for a variety of medical conditions. CRISPR applications are far-ranging - from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.

As a company that has been highly involved in genome-editing innovation, Merck recognizes that genome-editing has resulted in major positive advancements in biological research and medicine. At the same time, the growing potential of gene-editing technologies has opened scientific, legal and societal concerns. As both a user and supplier of gene-editing technology, Merck supports research with genome editing under careful consideration of ethical and legal standards. Merck has established a Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has defined a clear operational position taking into account scientific and societal issues while not blocking any promising therapeutic approaches for use in research and applications.

Merck has made significant contributions to the genome-editing field. It was the first company to offer custom biomolecules for genome editing globally (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving adoption of these techniques by researchers all over the world. Merck was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.

For more information on Merck’s work in the genome-editing field, visit https://www.merckgroup.com/en/stories/350-anniversary-its-all-in-the-genes.html and http://ar.merckgroup.com/2017/magazine/new-ways-of-identifying-disease.


For more information, contact
Gangolf Schrimpf
+49 6151 72 9591
Email


All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of €15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

   
Record changed: 2018-04-25

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px




» top